Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) EBT Margin (2022 - 2025)

Historic EBT Margin for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 18739.8%.

  • BioXcel Therapeutics' EBT Margin fell 101103600.0% to 18739.8% in Q3 2025 from the same period last year, while for Sep 2025 it was 8800.4%, marking a year-over-year decrease of 49348900.0%. This contributed to the annual value of 3520.39% for FY2024, which is 94830200.0% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' EBT Margin stood at 18739.8%, which was down 101103600.0% from 16536.67% recorded in Q2 2025.
  • BioXcel Therapeutics' EBT Margin's 5-year high stood at 449600.0% during Q1 2022, with a 5-year trough of 30559.85% in Q3 2022.
  • Moreover, its 4-year median value for EBT Margin was 8629.44% (2024), whereas its average is 18536.91%.
  • In the last 5 years, BioXcel Therapeutics' EBT Margin crashed by 2000000000bps in 2023 and then surged by 209009500bps in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' EBT Margin stood at 22826.89% in 2022, then skyrocketed by 74bps to 5947.87% in 2023, then skyrocketed by 35bps to 3868.03% in 2024, then plummeted by -384bps to 18739.8% in 2025.
  • Its EBT Margin was 18739.8% in Q3 2025, compared to 16536.67% in Q2 2025 and 8222.02% in Q1 2025.